- Home
- MHUA vs SYBX Comparison
MHUA vs SYBX Comparison
Compare MHUA & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- SYBX
- Stock Information
- Founded
- MHUA 1990
- SYBX N/A
- Country
- MHUA China
- SYBX United States
- Employees
- MHUA N/A
- SYBX N/A
- Industry
- MHUA Medical Specialities
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- MHUA Health Care
- SYBX Health Care
- Exchange
- MHUA Nasdaq
- SYBX Nasdaq
- Market Cap
- MHUA 15.6M
- SYBX 16.5M
- IPO Year
- MHUA 2022
- SYBX N/A
- Fundamental
- Price
- MHUA $0.32
- SYBX $1.46
- Analyst Decision
- MHUA
- SYBX Hold
- Analyst Count
- MHUA 0
- SYBX 3
- Target Price
- MHUA N/A
- SYBX $1.00
- AVG Volume (30 Days)
- MHUA 897.2K
- SYBX 25.8K
- Earning Date
- MHUA 09-20-2024
- SYBX 11-12-2024
- Dividend Yield
- MHUA N/A
- SYBX N/A
- EPS Growth
- MHUA 29.93
- SYBX N/A
- EPS
- MHUA 0.37
- SYBX N/A
- Revenue
- MHUA $94,252,537.00
- SYBX $2,777,000.00
- Revenue This Year
- MHUA N/A
- SYBX N/A
- Revenue Next Year
- MHUA N/A
- SYBX N/A
- P/E Ratio
- MHUA $0.89
- SYBX N/A
- Revenue Growth
- MHUA N/A
- SYBX 292.23
- 52 Week Low
- MHUA $0.25
- SYBX $1.22
- 52 Week High
- MHUA $1.47
- SYBX $3.73
- Technical
- Relative Strength Index (RSI)
- MHUA 37.70
- SYBX 53.64
- Support Level
- MHUA $0.30
- SYBX $1.36
- Resistance Level
- MHUA $0.35
- SYBX $1.47
- Average True Range (ATR)
- MHUA 0.03
- SYBX 0.08
- MACD
- MHUA 0.01
- SYBX 0.00
- Stochastic Oscillator
- MHUA 36.35
- SYBX 62.50
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.